You need to be logged in to view this video

Why We Still Need Covid-19 Oral Vaccines and Treatments

Released on Thursday, March 4, 2021•BIOTECH

Share
Facebook Twitter LinkedIn SMS

John McCamant, editor of The Medical Technology Stock Letter, is known for helping investors pick biotech winners. Join this session to discover a unique investment opportunity in a repurposed Phase II pill, poised to treat Covid-19 by reducing viral load.

John McCamant

Medical Technology Stock Letter, Editor

John McCamant joined the leading investment newsletter, Medical Technology Stock Letter, as an associate editor in 1987 and was named editor in August 2000. He has spent over 35 years on the front lines of biotechnology investing. In his previous role as an equities analyst for the American Healthcare fund, Mr. McCamant uncovered investment opportunities and guided investment strategy.